Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of -0.02 is 77% above its 1-year average of -0.08, near the high end of its 1-year range (-0.36–0.00).
As of the fiscal period ended Tuesday, June 30, 2026. 81.16% above its 12-month average of -0.09.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): -0.02.
DEBT TO EQUITY RATIO
-0.02
DEBT TO EQUITY RATIO AVG TTM
-0.09
DEBT TO EQUITY RATIO AVG 3Y
N/A
DEBT TO EQUITY RATIO AVG 5Y
N/A
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+81.16%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11
median of 774 covered companies
CURRENT VS SECTOR MEDIAN
-116.10%
vs the sector median at left
Neonc Technologies Holdings, Inc.
Market Cap
$77.54M
Debt to Equity Ratio
-0.02
TTM Avg
-0.09
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$78.07M
Debt to Equity Ratio
1.83
TTM Avg
0.28
3Y Avg
0.24
5Y Avg
0.19
Market Cap
$78.29M
Debt to Equity Ratio
0.05
TTM Avg
0.03
3Y Avg
0.03
5Y Avg
0.50
Market Cap
$76.74M
Debt to Equity Ratio
1.08
TTM Avg
4.17
3Y Avg
2.47
5Y Avg
1.68
Market Cap
$78.59M
Debt to Equity Ratio
0.00
TTM Avg
0.01
3Y Avg
0.01
5Y Avg
0.01
Market Cap
$79.03M
Debt to Equity Ratio
0.25
TTM Avg
0.08
3Y Avg
0.04
5Y Avg
0.04
Market Cap
$75.95M
Debt to Equity Ratio
6.60
TTM Avg
8.59
3Y Avg
8.59
5Y Avg
7.36
Market Cap
$79.61M
Debt to Equity Ratio
0.02
TTM Avg
0.02
3Y Avg
0.03
5Y Avg
0.03
Market Cap
$75.18M
Debt to Equity Ratio
1.43
TTM Avg
0.85
3Y Avg
0.55
5Y Avg
0.41
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Neonc Technologies Holdings, Inc. (NTHI) | $77.54M | -0.02 | -0.09 | N/A | N/A |
| Inovio Pharmaceuticals, Inc. (INO)vs › | $78.07M | 1.83 | 0.28 | 0.24 | 0.19 |
| Sera Prognostics, Inc. (SERA)vs › | $78.29M | 0.05 | 0.03 | 0.03 | 0.50 |
| Outset Medical, Inc. (OM)vs › | $76.74M | 1.08 | 4.17 | 2.47 | 1.68 |
| vTv Therapeutics Inc. (VTVT)vs › | $78.59M | 0.00 | 0.01 | 0.01 | 0.01 |
| Citius Oncology, Inc. (CTOR)vs › | $79.03M | 0.25 | 0.08 | 0.04 | 0.04 |
| SkinHealth Systems Inc. (SKIN)vs › | $75.95M | 6.60 | 8.59 | 8.59 | 7.36 |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $79.61M | 0.02 | 0.02 | 0.03 | 0.03 |
| Pulmonx Corporation (LUNG)vs › | $75.18M | 1.43 | 0.85 | 0.55 | 0.41 |
| Humacyte, Inc. (HUMA)vs › | $80.30M | 2.12 | 20.86 | 8.51 | 5.27 |
Debt/Equity
-0.02
Current Ratio
0.14
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | -0.02 |
| 2026-03-31 | -0.03 |
| 2025-12-31 | -0.36 |
| 2025-09-30 | -0.03 |
| 2025-06-30 | -0.03 |
| 2025-03-31 | 0.00 |
